Should Allakos Inc be on Your Investment Watchlist?
Allakos, Inc. (NASDAQ: ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial. The studies were evaluating the Company’s...
